Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ViiV Healthcare

ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
From ViiV Healthcare
Via Business Wire
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
From ViiV Healthcare
Via Business Wire
ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1
From ViiV Healthcare
Via Business Wire
ViiV Healthcare Announces Data Demonstrating Dovato (DTG/3TC) Is Highly Effective in Treatment-Naïve People With Advanced HIV
From ViiV Healthcare
Via Business Wire
ViiV Healthcare expands on real-world data supporting use of long-acting therapies in diverse patient populations at HIV Glasgow
From ViiV Healthcare
Via Business Wire
ViiV Healthcare Shows More Than 99% Effectiveness in Real-World Studies for Apretude (Cabotegravir Long-Acting), the Only Approved Long-Acting HIV PrEP, in Data Presented at IDWeek 2024
From ViiV Healthcare
Via Business Wire
ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries
From ViiV Healthcare
Via Business Wire
ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1
From ViiV Healthcare
Via Business Wire
ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024
From ViiV Healthcare
Via Business Wire
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
From ViiV Healthcare
Via Business Wire
ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges
From ViiV Healthcare
Via Business Wire
ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship to Improve HIV Prevention in Key Communities
From ViiV Healthcare
Via Business Wire
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
From ViiV Healthcare
Via Business Wire
ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
From ViiV Healthcare
Via Business Wire
ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)
From ViiV Healthcare
Via Business Wire
ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023
From ViiV Healthcare
Via Business Wire
ViiV Healthcare Announces Positive Data Demonstrating Long-acting Injectable Cabenuva (cabotegravir, rilpivirine) is as Effective as Daily Oral Biktarvy (BIC/FTC/TAF) for the Treatment of HIV-1
From ViiV Healthcare
Via Business Wire
ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023
From ViiV Healthcare
Via Business Wire
Major Corporations Launch New Coalition to Help End HIV in the United States
From ViiV Healthcare
Via Business Wire
ViiV Healthcare Unveils a New Global Study Revealing Three Quarters of People Believe There Are Still Negative Perceptions When It Comes to People Living With HIV
From ViiV Healthcare
Via Business Wire
ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV
From ViiV Healthcare
Via Business Wire
ViiV Healthcare Presents Positive Data Showing Vocabria (cabotegravir) and Rekambys (rilpivirine) Can Be Successfully Implemented Across a Range of European Healthcare Settings
From ViiV Healthcare
Via Business Wire
ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced
From ViiV Healthcare
Via Business Wire
ViiV Healthcare Announces New Data at AIDS 2022 From Unblinded Phase of HPTN 084 Study in Women in Sub-Saharan Africa Showing Continued Superior Efficacy of Injectable Cabotegravir Long-Acting for PrEP Over Daily, Oral TDF/FTC Tablets
From ViiV Healthcare
Via Business Wire
ViiV Healthcare and the Medicines Patent Pool Sign New Voluntary Licensing Agreement to Expand Access to Innovative Long-Acting HIV Prevention Medicine
From ViiV Healthcare
Via Business Wire
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg
From ViiV Healthcare
Via Business Wire
ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period
From ViiV Healthcare
Via Business Wire
ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022
From ViiV Healthcare
Via Business Wire
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment
From ViiV Healthcare
Via Business Wire
ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention
From ViiV Healthcare
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.